BioNTech SE

NasdaqGS:BNTX 株式レポート

時価総額：US$23.6b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

BioNTech 将来の成長

Future 基準チェック /16

BioNTech利益と収益がそれぞれ年間23.5%と8.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-1.7% 24.7%なると予測されています。

主要情報

19.3%

収益成長率

19.0%

EPS成長率

Biotechs 収益成長29.8%
収益成長率8.8%
将来の株主資本利益率-2.5%
アナリストカバレッジ

Good

最終更新日09 Sep 2024

今後の成長に関する最新情報

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08
Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

Recent updates

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Sep 13
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Aug 20

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16
Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11
Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08
Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24
BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09
BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18
Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02
Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22
Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11
BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13
Is BioNTech (NASDAQ:BNTX) A Risky Investment?

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23
A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29
BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

Mar 05
These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Feb 18
A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02
Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26
With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

業績と収益の成長予測

NasdaqGS:BNTX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20262,752-681-758-74415
12/31/20252,710-636-955-51419
12/31/20242,733-5231231,01319
6/30/20242,691-5042,3522,972N/A
3/31/20242,7301134,9445,732N/A
12/31/20233,8199304,6665,371N/A
9/30/20236,6182,7514,6905,350N/A
6/30/20239,1844,3758,7269,317N/A
3/31/202312,2136,2388,4938,850N/A
12/31/202217,3119,43413,21413,577N/A
9/30/202218,56510,32212,27712,549N/A
6/30/202221,19111,7489,0409,271N/A
3/31/202223,30312,8635,0665,251N/A
12/31/202118,97710,293736890N/A
9/30/202113,7907,4931,1981,338N/A
6/30/20217,7704,072-474-355N/A
3/31/20212,5031,197-376-270N/A
12/31/202048215-99-13N/A
9/30/2020165-410-382-326N/A
6/30/2020126-230-239-183N/A
3/31/2020110-192-268-222N/A
12/31/2019109-179-270-198N/A
9/30/2019144-122-220-138N/A
6/30/2019136-116-142-75N/A
3/31/2019132-77-136-55N/A
12/31/2018128-48-126-59N/A
12/31/201762-86N/A-53N/A

アナリストによる今後の成長予測

収入対貯蓄率: BNTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BNTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BNTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BNTXの収益 ( 8.8% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: BNTXの収益 ( 5.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BNTX 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y